Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

McKesson
Baxter
Mallinckrodt
AstraZeneca
Johnson and Johnson
Harvard Business School

Last Updated: November 26, 2022

CLINICAL TRIALS PROFILE FOR ZOLADEX


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Zoladex

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002597 ↗ Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer Completed National Cancer Institute (NCI) Phase 3 1994-10-01 RATIONALE: Radiation therapy (RT) uses high-energy x-rays to damage tumor cells. Androgens can stimulate the growth of prostate cancer cells. Hormone therapy using flutamide, goserelin, and leuprolide may fight prostate cancer by reducing the production of androgens. It is not yet known which regimen of antiandrogen therapy is most effective for prostate cancer. PURPOSE: Randomized phase III trial to study the effectiveness of radiation therapy with or without antiandrogen therapy in treating patients who have stage I or stage II prostate cancer.
NCT00002597 ↗ Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer Completed Radiation Therapy Oncology Group Phase 3 1994-10-01 RATIONALE: Radiation therapy (RT) uses high-energy x-rays to damage tumor cells. Androgens can stimulate the growth of prostate cancer cells. Hormone therapy using flutamide, goserelin, and leuprolide may fight prostate cancer by reducing the production of androgens. It is not yet known which regimen of antiandrogen therapy is most effective for prostate cancer. PURPOSE: Randomized phase III trial to study the effectiveness of radiation therapy with or without antiandrogen therapy in treating patients who have stage I or stage II prostate cancer.
NCT00003645 ↗ Randomized Trial of Adjuvant Hormonal Therapy in Surgically Treated Prostate Cancer Patients at High Risk for Recurrence Terminated AstraZeneca Phase 3 1999-06-14 RATIONALE: Testosterone can stimulate the growth of prostate cancer cells. Hormone therapy using leuprolide and flutamide may fight prostate cancer by reducing the production of testosterone. It is not yet known whether receiving leuprolide and flutamide is more effective than receiving no further therapy. PURPOSE: Randomized phase III trial to determine the effectiveness of hormone therapy in treating patients who have stage I or stage II prostate cancer that is at high risk of recurrence and who have already undergone surgery.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Zoladex

Condition Name

Condition Name for Zoladex
Intervention Trials
Prostate Cancer 53
Breast Cancer 27
Prostate Adenocarcinoma 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Zoladex
Intervention Trials
Prostatic Neoplasms 82
Breast Neoplasms 46
Adenocarcinoma 21
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Zoladex

Trials by Country

Trials by Country for Zoladex
Location Trials
United States 620
Canada 39
China 22
United Kingdom 15
Japan 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Zoladex
Location Trials
California 31
Texas 28
Massachusetts 22
Maryland 21
Illinois 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Zoladex

Clinical Trial Phase

Clinical Trial Phase for Zoladex
Clinical Trial Phase Trials
Phase 4 11
Phase 3 42
Phase 2/Phase 3 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Zoladex
Clinical Trial Phase Trials
Completed 63
Recruiting 21
Active, not recruiting 20
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Zoladex

Sponsor Name

Sponsor Name for Zoladex
Sponsor Trials
National Cancer Institute (NCI) 35
AstraZeneca 17
M.D. Anderson Cancer Center 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Zoladex
Sponsor Trials
Other 165
Industry 71
NIH 39
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Moodys
Merck
Baxter
AstraZeneca
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.